<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001263" GROUP_ID="INFECTN" ID="527100012414523971" MERGED_FROM="" MODIFIED="2008-11-11 12:44:13 +0100" MODIFIED_BY="Reive Robb" REVIEW_NO="MSAM" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2008-11-10 15:20:20 +0000" MODIFIED_BY="[Empty name]">
<TITLE>Interventions for treating melioidosis</TITLE>
<CONTACT>
<PERSON ID="4958" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Miny</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Samuel</LAST_NAME>
<SUFFIX/>
<POSITION>Health Technology Assessment and Clinical Evidence Reviewer</POSITION>
<EMAIL_1>msamuel@rti.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Research Triangle Institute-Health Solutions</ORGANISATION>
<ADDRESS_1>Williams House, Lloyd Street North</ADDRESS_1>
<ADDRESS_2>Manchester Science Park</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M15 6SE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 2324923</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 2323409</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-10 15:04:18 +0000" MODIFIED_BY="Harriet MacLehose">
<PERSON ID="4958" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Miny</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Samuel</LAST_NAME>
<SUFFIX/>
<POSITION>Health Technology Assessment and Clinical Evidence Reviewer</POSITION>
<EMAIL_1>msamuel@rti.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Research Triangle Institute-Health Solutions</ORGANISATION>
<ADDRESS_1>Williams House, Lloyd Street North</ADDRESS_1>
<ADDRESS_2>Manchester Science Park</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M15 6SE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 2324923</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 2323409</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DF30A89482E26AA200BB9F5B1BDCED75" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>TY</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ti</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>phctity@nus.edu.sg</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pharmacology, Faculty of Medicine, MD2</DEPARTMENT>
<ORGANISATION>National University of Singapore</ORGANISATION>
<ADDRESS_1>18 Medical Drive</ADDRESS_1>
<ADDRESS_2/>
<CITY>Singapore</CITY>
<ZIP>117597</ZIP>
<REGION/>
<COUNTRY CODE="SG">Singapore</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-24 15:11:19 +0100" MODIFIED_BY="Miny Samuel">
<UP_TO_DATE>
<DATE DAY="18" MONTH="8" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="8" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-10 15:19:22 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-10 15:19:22 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-10 15:20:20 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-10 15:20:20 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="8" YEAR="2004"/>
<DESCRIPTION>
<P>New studies sought but none found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-10 15:19:12 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="8" YEAR="2002"/>
<DESCRIPTION>
<P>Two trials added (<LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK> and <LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-10 15:18:54 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="7" YEAR="2002"/>
<DESCRIPTION>
<P>Search updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Trials &amp; Epidemiology Research Unit, National Medical Research Council</NAME>
<COUNTRY CODE="SG">Singapore</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>National University of Singapore, Department of Pharmacology</NAME>
<COUNTRY CODE="SG">Singapore</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-10 15:23:00 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-02 14:02:33 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-02 14:01:47 +0000" MODIFIED_BY="[Empty name]">Interventions for treating melioidosis</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-02 14:02:33 +0000" MODIFIED_BY="[Empty name]">
<P>Plain language summary pending.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-10 15:04:38 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Melioidosis is an infectious disease that occurs in tropical regions, particularly in Thailand. It is caused by the bacterium Burkholderia pseudomallei and is a serious condition which can be fatal. Beta-lactam antibiotics have dramatically reduced the risk of death, but mortality still remains high.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To summarize reliable evidence on the effects of treatment regimens on death and relapse.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (August 2004), CENTRAL (<I>The Cochrane Library</I> Issue 3, 2004), MEDLINE (1966 to August 2004), EMBASE (1980 to August 2004), BIOSIS (up to August 2004), Health Star (up to August 2004), and reference lists of articles. We also contacted pharmaceutical companies and researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized and quasi-randomized controlled trials comparing antibiotic regimens in people with melioidosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-19 12:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed the eligibility of studies and the risk of bias in the trials. Adverse effects information was collected from the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-10 15:04:38 +0000" MODIFIED_BY="[Empty name]">
<P>Nine trials, all from Thailand, involving a total of 872 participants were included. For intravenous therapy in the acute phase, we identified six trials with a total of 619 participants. Chloramphenicol, doxycycline, and co-trimoxazole (trimethoprim-sulphamethoxazole) combination regimens were associated with a mortality of 50% or more (two studies). Participants randomized to regimens including ceftazidime were more likely to survive (risk ratio [RR] 0.46; 95% confidence interval [CI] 0.30 to 0.71). When ceftazidime-containing regimens were compared with beta-lactam or alternative beta-lactamase inhibitor regimens such as co-amoxiclav (amoxycillin-clavulanic acid) and cefoperazone-sulbactam, or with imipenem, mortality rates were similar (RR 1.06; 95% CI 0.81 to 1.39). For oral therapy in the maintenance phase, we found three trials of 253 participants. They compared the conventional regimen (chloramphenicol, doxycycline, and trimethoprim-sulphamethoxazole) with other regimens (amoxycillin-clavulanic acid, ciprofloxacin-azithromycin, and doxycycline alone). There were fewer deaths with the conventional regimen, but no statistically significant differences demonstrated.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Regimens for the acute phase of illness should contain ceftazidime or imipenem. It is not yet clear if combinations of treatments in the early phase reduce relapse. For oral therapy after the acute phase of treatment, trials suggest that conventional four drug regimens can be used for treatment. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-10 15:23:00 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-10 15:13:01 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Definition</HEADING>
<P>Melioidosis is an infectious disease caused by the Gram-negative bacterium Burkholderia pseudomallei (formerly known as Pseudomonas pseudomallei). B. pseudomallei is found as a free living organism in the natural environment, especially in surface water of rice paddies, fields newly planted with oil palm, drains, gardens, and playgrounds in endemic areas. In humans, infection is thought to be caused primarily by direct contact with contaminated soil or water through inoculation (<LINK REF="REF-Dance-2000a" TYPE="REFERENCE">Dance 2000a</LINK>). Other routes of infection are believed to be by ingestion or inhalation of environmental organisms (<LINK REF="REF-Chaowagul-1989" TYPE="REFERENCE">Chaowagul 1989</LINK>; <LINK REF="REF-Leelarasamee-1989" TYPE="REFERENCE">Leelarasamee 1989</LINK>; <LINK REF="REF-Inglis-2001" TYPE="REFERENCE">Inglis 2001</LINK>), but this has to be further investigated (<LINK REF="REF-Currie-2000" TYPE="REFERENCE">Currie 2000</LINK>). Infected humans and other animals might also play a role in the transmission of the bacterium to new environments since B. pseudomallei is found in sputum, pus, urine, and faeces of infected individuals (<LINK REF="REF-Dance-2000b" TYPE="REFERENCE">Dance 2000b</LINK>). It is thought that the virulence of the infecting strain and the susceptibility of the host influence who develops the disease (<LINK REF="REF-Dance-2000a" TYPE="REFERENCE">Dance 2000a</LINK>).</P>
<P>Most people who are infected remain asymptomatic. The infection can remain latent for years because the bacterium is able to reside in the body for extensive periods. There are reports of people developing illness 24 to 26 years after leaving the endemic area (<LINK REF="REF-Mays-1975" TYPE="REFERENCE">Mays 1975</LINK>; <LINK REF="REF-Jenkins-1990" TYPE="REFERENCE">Jenkins 1990</LINK>; <LINK REF="REF-Wilks-1994" TYPE="REFERENCE">Wilks 1994</LINK>). The intracellular mechanisms that enable B. pseudomallei to survive and reside within the host phagocytic cells for long periods are not well understood (<LINK REF="REF-Leelarasamee-1998" TYPE="REFERENCE">Leelarasamee 1998</LINK>). The factors influencing the reactivation of the pathogen are also not well understood, but are thought to be dependent on immunodepression and stress of the individual (<LINK REF="REF-Leelarasamee-1989" TYPE="REFERENCE">Leelarasamee 1989</LINK>; <LINK REF="REF-Perret-1998" TYPE="REFERENCE">Perret 1998</LINK>).</P>
<P>Clinical manifestations of the disease vary considerably, from acute disease to chronic localized infection (<LINK REF="REF-Howe-1971" TYPE="REFERENCE">Howe 1971</LINK>). Acute disease can be acute pulmonary or acute septicaemic forms, which are often fatal. People with the mild illness may present to health services with a localized infection or fever. If untreated, the condition may progress to acute sepsis with the bacteria circulating in the blood, pus, urine, and other bodily tissues and secretions (<LINK REF="REF-Brett-2000" TYPE="REFERENCE">Brett 2000</LINK>). These people have high fever, and sometimes abscesses in the lungs, liver, spleen, and other organs. The disease is more common in people with diabetes and renal failure, but can also occur in individuals with decreased immunity due to other causes (<LINK REF="REF-Leelarasamee-1989" TYPE="REFERENCE">Leelarasamee 1989</LINK>; <LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>).</P>
<P>Melioidosis has been described as 'the great imitator' of diseases such as malaria, typhoid fever, leptospirosis, tuberculosis, and other bacterial and mycotic infections (<LINK REF="REF-Leelarasamee-1989" TYPE="REFERENCE">Leelarasamee 1989</LINK>), as virtually every organ can be affected. Other localized infections, in the form of acute suppurative parotiditis (inflammation of the parotid gland in the ear) or chronic granulomatous lesions, are unique presentations of B. pseudomallei infection that may occur in adults, but are largely confined to children (<LINK REF="REF-Dance-1989" TYPE="REFERENCE">Dance 1989</LINK>; <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Incidence</HEADING>
<P>The disease occurs in regions between the latitudes of 20 degrees north and 20 degrees south. It is found in South East Asia and northern Australia, but is most common in Thailand (<LINK REF="REF-Ip-1995" TYPE="REFERENCE">Ip 1995</LINK>; <LINK REF="REF-Leelarasamee-2000" TYPE="REFERENCE">Leelarasamee 2000</LINK>). Incidence in Thailand is highest in the rainy season (<LINK REF="REF-Dance-1991" TYPE="REFERENCE">Dance 1991</LINK>; <LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>), and more common in people living in rural areas. At present, 2000 to 3000 cases of clinical melioidosis are estimated to occur each year in Thailand (<LINK REF="REF-Leelarasamee-2000" TYPE="REFERENCE">Leelarasamee 2000</LINK>). Some cases have been reported from temperate zones over the years (<LINK REF="REF-Perret-1998" TYPE="REFERENCE">Perret 1998</LINK>; <LINK REF="REF-Minassian-1999" TYPE="REFERENCE">Minassian 1999</LINK>), but the overall incidence rate in these countries is not clear (<LINK REF="REF-Dance-2000a" TYPE="REFERENCE">Dance 2000a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Prognosis</HEADING>
<P>Prognosis is poor. Detection of the bacterium in blood culture in severe disease is associated with higher mortality. In one study 74% of people with a positive blood culture died within 24 hours (<LINK REF="REF-Tiangpitayakorn-1997" TYPE="REFERENCE">Tiangpitayakorn 1997</LINK>). Mortality is high in severe disease (septicaemic form of melioidosis) in which the clinical course often deteriorates rapidly even with the currently available treatments, with disseminated infection associated with 40% to 90% of people dying. In people with septicaemia with only one organ involved, death rates are in the region of 20%. Treatment with the antibiotics ceftazidime and imipenem seems to reduce the number of deaths, although the number remains high.</P>
<P>Prolonged oral therapy is required to control the melioidosis infection following intravenous treatment, and relapse is found to be very common during and after the treatment. Relapse of melioidosis infection is defined as the development of new symptoms and signs of the infection together with a positive culture for B. pseudomallei from blood or sites that had previously been negative. It is associated with the ability of the bacteria to form microcolonies in damaged tissues and survive within phagocytic cells. Despite long, high dose courses of antibiotics, there have been reports of high relapse rates both bacteriologically and clinically, and half of those who clinically relapse subsequently die (<LINK REF="REF-Chaowagul-1993" TYPE="REFERENCE">Chaowagul 1993</LINK>; <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>). People with severe disease (multiple foci of infection or septicaemia) relapse more frequently than those with localized melioidosis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment</HEADING>
<P>Currently, regimens of several antibiotics are in use, including third generation cephalosporins such as ceftazidime; third generation carbapenems such as imipenem; chloramphenicol; tetracycline; co-trimoxazole (trimethoprim-sulphamethoxazole); fluoroquinolones; and other beta-lactam/beta-lactamase inhibitor combinations such as co-amoxiclav (amoxycillin-clavulanic acid) and cefoperazone-sulbactam. The newer drugs, particularly the third generation cephalosporins and carbapenems, are expensive and therefore it is important to establish their comparative effectiveness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Aims of review</HEADING>
<P>Mortality rates of 80% to 90% in severe disease are associated with older antimicrobial agents such as chloramphenicol, doxycycline, and trimethoprim-sulphamethoxazole (<LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>; <LINK REF="REF-Chaowagul-1993" TYPE="REFERENCE">Chaowagul 1993</LINK>). After the introduction of ceftazidime, a third generation cephalosporin, mortality rates have halved (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). In some areas, however, older antimicrobial agents are still being used.</P>
<P>This review aims to summarize existing evidence around benefits and harms of treatment regimens for melioidosis. In particular, it aims to assess new drugs and new regimens in the acute phase of treatment, including third generation cephalosporins and carbapenems. Relapse after the acute phase remains a problem, particularly with four drug regimens given for 8 to 20 weeks, which means poor adherence is likely to compound the situation and preventing relapse with effective agents will remain a problem. We started out with the following questions.</P>
<P>1. What are the comparative effects of ceftazidime and other beta-lactam antibiotics compared with older antibiotics on death?</P>
<P>2. What are the comparative effects of other new compounds compared with existing best regimens?</P>
<P>3. What are the comparative effects of conventional regimens compared with other regimens for oral therapy?</P>
<P>4. What adverse effects are caused by the regimens?</P>
<P>5. Which route of administration of drugs is more effective in severe melioidosis (infusion/bolus injection)?</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-19 12:27:34 +0100" MODIFIED_BY="[Empty name]">
<P>To summarize reliable evidence on the effects of treatment regimens on death and relapse. Specifically, to:</P>
<P>1. To summarize the effects of ceftazidime in the acute disease compared with regimens of older antibiotics on death, treatment failure, and relapse.</P>
<P>2. To summarize the comparative effects of regimens containing new drugs (such as cefoperazone combined with sulbactam, and imipenem) on ceftazidime-containing regimens on death, treatment failure, and relapse.</P>
<P>3. To evaluate regimens given after the acute phase of treatment known commonly as oral maintenance therapy on relapse and death.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-10 15:04:49 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-08-19 12:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized or quasi-randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-19 12:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>People with a diagnosis of melioidosis that is clinically confirmed by bacteriological culture (bacterial infection by Burkholderia [Pseudomonas] pseudomallei) or by clinical presentation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-10 15:04:47 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Regimens of antibiotics including ceftazidime, imipenem, chloramphenicol/doxycycline/co-trimoxazole (trimethoprim-sulphamethoxazole), co-amoxiclav (amoxycillin-clavulanic acid), cefoperazone-sulbactam, ciprofloxacin, azithromycin, and other new antibiotic compounds.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>Comparative antibiotic regimens.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-10 15:04:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Death.</LI>
<LI>Clinical relapse.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Adverse effects of the drugs.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>We have attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<P>We searched the Cochrane Infectious Diseases Group Specialized Register for relevant trials up to August 2004 using the search terms: Burkholderia; Pseudomallei; and melioidosis. Full details of the Cochrane Infectious Diseases Group methods and the journals hand searched are published in The Cochrane Library in the section on Collaborative Review Groups.</P>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library </I>(Issue 3, 2004) using the search terms: Burkholderia; Pseudomallei; and melioidosis. This contains mainly reference information to randomized controlled trials and controlled clinical trials in health care.</P>
<P>We used the search terms 'Pseudomallei' and 'melioidosis' to search the following electronic databases in combination with the search strategy developed by the Cochrane Collaboration and detailed in the Cochrane Reviewers' Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>): MEDLINE (1966 to August 2004); EMBASE (1980 to August 2004); BIOSIS (up to August 2004); and Health Star (up to August 2004).</P>
<P>We contacted pharmaceutical companies for unpublished, ongoing, and planned trials.</P>
<P>The external referees were asked to check the completeness of the search strategy and to identify any additional unpublished, ongoing and planned trials.</P>
<P>We consulted the authors of some of the included studies to ask if we had missed any published or unpublished trials.</P>
<P>We checked the reference lists of all trials identified by the above methods.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-19 12:57:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-08-19 12:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>We screened the abstracts of potentially relevant trials for randomized controlled trials and quasi-randomized controlled trials. We used the titles and abstracts of the identified citations to exclude trials that clearly did not meet the inclusion criteria. If either reviewer judged that the trial might meet the criteria, we obtained the full paper. We independently screened the full articles of selected trials to confirm eligibility. We were not blinded to the identity of the papers.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-19 12:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>We independently extracted data using the piloted data extraction form.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-19 12:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>We independently extracted the data and evaluated the risk of bias in each trial in terms of adequacy of concealment of allocation, generation of allocation sequence, blinding, and follow up of participants, using the standard methods for the Cochrane Infectious Diseases Group. We also checked whether authors had conducted an intention-to-treat analysis. We contacted trialists to supply missing information and to clarify points. We resolved discrepancies through discussion and consensus.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-08-19 12:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>We used risk ratio and the fixed effect model when there was no statistically significant heterogeneity. Where there was statistically significant heterogeneity we intended to explore this in relation to total dose of the main comparator drug given, co-interventions (other drugs used in experimental or comparator arm), and presence of underlying disease. With oral therapy, we also intended to explore adherence to the regimens as a source of heterogeneity between trials. Where it was not possible to explain heterogeneity, we also used a a random effect model.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>We identified nine trials, all from Thailand and all meeting the inclusion criteria (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Six studied intravenous therapy for acute infection (<LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>; <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>; <LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>; <LINK REF="STD-Suputtamongkol-1994a" TYPE="STUDY">Suputtamongkol 1994a</LINK>; <LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>); and three trials studied oral treatment given after acute infections, or in people with mild disease (<LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>; <LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK>; <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>). Study sample size ranged from 38 to 214 participants.</P>
<P>Most of the participants included in these studies had some underlying disease, mainly diabetes mellitus or chronic renal failure. This ranged from 21.9% to 100%. Although overall therapeutic failures (death, number of participants switched to alternate drug) were reported in studies, the highest reported was in <LINK REF="STD-Suputtamongkol-1994a" TYPE="STUDY">Suputtamongkol 1994a</LINK> (ceftazidime 29%, and amoxycillin-clavulanate 35%).</P>
<SUBSECTION>
<HEADING LEVEL="3">Intravenous regimens</HEADING>
<P>Six trials examined intravenous treatment given to inpatients with evidence of culture-proven infection; information on the outcomes was available for a total of 619 participants (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>; <LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>; <LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>; <LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>; <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>, <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). All participants had moderate to severe disease, based on clinical signs (fever, tachycardia, raised respiratory rate, blood pressure less than 90/60 mm Hg) and combined with evidence of disseminated infection (blood-borne pneumonia, multiple cutaneous abscesses or multiple abscesses in two or more internal organs). Various tests were conducted, including blood culture, and treatment was started based on the clinical diagnosis. These studies examined the effects of ceftazidime (alone or in combination) against existing conventional or newer treatments that did not contain ceftazidime.</P>
<P>Of the six studies included in the analysis, only three of them clearly indicated that they had included participants who had died within 48 hours for the analysis (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>; <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>; <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). The trial endpoint for all the five trials was either survival or death at the end of intravenous therapy (7 days in <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK> and <LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>; 10 to 16 days in <LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK> and <LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>; 10 to 14 days in the trial by <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK> and 26 days in the trial by <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). Daily antibiotic dosing varied between studies. In studies using ceftazidime alone, the dosage was 120 mg/kg/day (two studies); when used in combination, the dose was 100 mg/kg/day.</P>
<P>Bacterial clearance was also tested in all the trials, but the sampling time varied in the trials.</P>
<P>
<LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK> stopped randomization when the interim analysis point had been reached. This was because of difficulties in ensuring continuation of the antibiotic supply from the drug companies after three years. They therefore enrolled only 296 participants from 1994 to 1996; only 214 had melioidosis confirmed by culture and they were treated for a minimum of 10 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral regimens</HEADING>
<P>Three studies, including a total of 253 participants, examined oral regimens. One examined the effect of oral co-amoxiclav (amoxycillin + clavulanic acid) with the conventional four drug regimen of chloramphenicol + doxycycline + co-trimoxazole (trimethoprim + sulphamethoxazole) (<LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>). The second examined the effect of doxycycline alone against the conventional regimen (<LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>), and the third trial examined the effect of ciprofloxacin and azithromycin compared to the conventional co-trimoxazole (trimethoprim + sulphamethoxazole) plus doxycycline (<LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK>). The participants were a mixture of survivors from severe melioidosis (after parenteral treatment); and people with non-severe or localized culture-proven melioidosis whom clinicians judged unlikely to progress to septicaemia. The proportion of people falling into the two categories was provided by the authors.</P>
<P>In <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>, participants were asked to return for follow-up examinations every 2 to 4 weeks until they finished their treatment period of 20 weeks. Compliance with the drug therapy was checked by interview. The number completing 12 weeks and 20 weeks was similar in the two groups, but low overall (12 week completion rate = 72% overall [72/101]; 20 week completion rate = 54% [54/101]). A cure was defined as complete recovery with no evidence of relapse after at least one and half years (median duration) of follow up.</P>
<P>In <LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>, the treatment period was between 12 and 20 weeks. The median duration of treatment was 18 weeks for the conventional regimen and 12 weeks for doxycycline. They reported that compliance to both drugs was not formally assessed. An informal questioning of the participants, however, revealed that there was no evidence to show compliance with doxycycline was worse than with the conventional regimen. The authors believe that the combination of large doses and a large number of capsules or tablets per dose (2 tablets per day for doxycycline and 14 tablets for conventional regimen) and a high incidence of adverse effects might have contributed to the poor compliance. Sixteen participants were lost to follow up in the study (including seven in the conventional regimen group) and the outcome of the infections was unknown. The reasons for loss to follow up were not stated in the article.</P>
<P>In <LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK>, the median duration of oral treatment was 12 weeks for the combination of ciprofloxacin and azithromycin, and 20 weeks for the conventional regimen. Participants were asked to attend follow up every four to six weeks during treatment and thereafter every four to eight weeks. Compliance to the medication was assessed by asking the participants to return the remaining medication. The number completing 12 weeks and 20 weeks was similar in the two groups, (12 week completion rate = 26/32 [81%]; 20 week completion rate = 26/33 [79%]). The median duration of follow up was shorter in the ciprofloxacin group (220 days; range 40 to 501) compared to the conventional regimen group (277 days; range 55 to 533).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>Only two studies reported clearly on concealment of allocation (<LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>; <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). Randomization was through sealed envelopes opened after the participant was enrolled (<LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>). One study reported allocation from computer-generated random numbers (<LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>), two trials were randomized in pairs (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>; <LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>), and two studies were reported as double blind (<LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>; <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>).</P>
<P>
<LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK> reported exclusion because of severe drug allergies during the trials (two in the conventional treatment and one in the new regimen), but it was less than 5%. Two of the 40 participants (5%) in <LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK> were excluded from the study because of inadequate information.</P>
<P>
<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>, <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>, <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>, and <LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK> reported that they used intention-to-treat analysis.</P>
<P>All participants who were entered in the trials were accounted for and attributed at the end of the study. For oral maintenance therapy, compliance to treatment and follow-up visits were poor, but was similar in both treatment arms (<LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>; <LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>). In <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK> and <LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>, 19.8% and 14.7% of participants were lost to follow up, respectively.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Intravenous treatment: ceftazidime compared with other regimens</HEADING>
<P>Death rates were high in trial arms using the older conventional regimens of chloramphenicol, doxycycline, and co-trimoxazole (trimethoprim-sulphamethoxazole): 74% in <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK> and 47% in <LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>. There were fewer deaths in participants treated with ceftazidime compared with the conventional regimen (chloramphenicol + doxycycline + trimethoprim-sulphamethoxazole) (risk ratio 0.46; 95% confidence interval 0.30 to 0.71). Overall mortality in the regimens containing ceftazidime, across the two trials, was 29%.</P>
<P>In studies comparing ceftazidime regimens against other newer regimens there was no obvious difference in mortality. These comparisons were against co-amoxiclav (amoxycillin-clavulanic acid) with 144 participants (<LINK REF="STD-Suputtamongkol-1994a" TYPE="STUDY">Suputtamongkol 1994a</LINK>), and imipenem with 214 participants (<LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK>). Two studies of cefoperazone-sulbactam with a total of 138 participants was inconclusive (<LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>; <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). The small study favoured cefoperazone-sulbactam (risk ratio 1.33; 95% confidence interval 0.34 to 5.17) (<LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>), but the bigger study favoured the ceftazidime regimen (risk ratio 0.78, 95% confidence interval 0.31 to 1.93) (<LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>). Overall mortality in these trials, that is, death in both arms totalled across all three trials, was 28.8%.</P>
<P>Reporting of bacterial clearance varied between studies because of the selection of varying time intervals. Bacterial clearance was reported at 72 hours in one study (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>), and at 24 hours in the others. None of the studies showed an impact of any one particular regimen on bacterial clearance, and generally high levels of persistent bacteraemia were demonstrated in all treatment groups.</P>
<P>In participants given ceftazidime alone and in their comparator arms given conventional regimens, there were no reports of adverse effects (<LINK REF="REF-Suputtamongkol-1994b" TYPE="REFERENCE">Suputtamongkol 1994b</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). In participants given the conventional regimen, there were reports of severe haemolysis and aplastic anaemia in two participants; in the other arm of ceftazidime in combination with trimethoprim-sulphamethoxazole there was only one report of haemolysis (<LINK REF="STD-Sookpranee-1992" TYPE="STUDY">Sookpranee 1992</LINK>). There were no reports of adverse effects in participants treated with amoxicillin-clavulanic acid; but with cefoperazone-sulbactam in combination with trimethoprim-sulphamethoxazole, one participant developed autoimmune haemolytic anaemia on the fifth day of treatment (<LINK REF="STD-Thamprajamchit-1998" TYPE="STUDY">Thamprajamchit 1998</LINK>). With imipenem treatment, <LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK> reported generalized convulsion in one participant; in the other treatment arm, only one participant reported rash with use of ceftazidime. Two participants were reported to have developed autoimmune hemolytic anaemia on the 5th and the 25th day after being treated with ceforperazone-sulbactam in <LINK REF="STD-Chetchotisakd-2001a" TYPE="STUDY">Chetchotisakd 2001a</LINK>.</P>
<P>Of the six studies on intravenous therapy, only four of them reported adverse effects. The nature of the reported adverse effects varied within trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral treatment</HEADING>
<P>There were three studies on oral maintenance therapy.</P>
<P>In a comparison of amoxycillin-clavulanic acid with the conventional regimen (chloramphenicol, doxycycline, trimethoprim-sulphamethoxazole), there was no obvious difference in deaths between the two arms, but numbers were small. The median duration of follow up was 1.5 years (range 3 weeks to 4.2 years) in the oral conventional group compared to 1.3 years (range 3 weeks to 4.1 years) in the amoxycillin-clavulanic acid group (<LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>); overall relapse was relatively low in this study (3/101 participants). However, fewer adverse effects were reported in the amoxycillin-clavulanic acid group, but this was not statistically significant.</P>
<P>In a comparison between doxycycline and a combination of conventional drugs (chloramphenicol, doxycycline, trimethoprim-sulphamethoxazole), there were more deaths in the single agent group (10/43 compared with 4/44), but the numbers were small and no statistically significant difference was detected (<LINK REF="STD-Chaowagul-1999" TYPE="STUDY">Chaowagul 1999</LINK>). The relapse rates in this study were much higher compared with <LINK REF="STD-Rajchanuvong-1995" TYPE="STUDY">Rajchanuvong 1995</LINK>, which could reflect differences in participant mix. Adverse effects were recorded in both groups, with no obvious difference between the groups, although the number of participants was small.</P>
<P>In a comparison of ciprofloxacin-azithromycin with the conventional regimen (trimethoprim, sulfamethoxazole, and doxycycline) in <LINK REF="STD-Chetchotisakd-2001b" TYPE="STUDY">Chetchotisakd 2001b</LINK>, there was one reported death in the cefoperazone group. There were more clinical relapses in the cefoperazone group compared to the conventional regimen (risk ratio 3.09; 95% confidence interval 0.92 to 10.40). The number of adverse effects reported were higher in the conventional regimen group (risk ratio 0.77; 95% confidence interval 0.19 to 3.19).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-10 15:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>The trial data confirm the benefit of ceftazidime and imipenem - the newer drugs for parenteral treatment of severe melioidosis infection - compared with older antimicrobial agents such as chloramphenicol, doxycycline, and co-trimoxazole (trimethoprim-sulphamethoxazole). These findings do not show any dramatic difference in effectiveness between beta-lactam/beta-lactamase inhibitor regimens.</P>
<P>All trials have provided a long course of oral maintenance therapy following successful intravenous therapy. Only three comparative studies of these regimens have been conducted so far. Each of them have different drugs in their comparator arm and two of the studies showed relapse was lower in the participants receiving four drugs. For the conventional regimen, participants are required to take up to 14 tablets per day, which could impair adherence to these regimens.</P>
<P>The cost of treatment is high, especially with beta-lactam regimens. The cost of ceftazidime varies from US $70 to $100 per day for participants diagnosed with severe melioidosis, which is approximately six to seven times higher than the cost of conventional regimens. Imipenem, an alternative to ceftazidime, also costs about US $150 per day per person. Since most people are from rural areas in countries where the foreign exchange budgets for drugs are severely limited, it is particularly important that the most cost-effective regimens are determined, including the length of treatment required.</P>
<P>
<LINK REF="STD-Simpson-1999" TYPE="STUDY">Simpson 1999</LINK> comments that the pharmaceutical industry shows little interest in this area because the disease mainly affects poor rural people. Researchers, on the other hand, may find it difficult to conduct studies without the help of some funding bodies since the drugs are very expensive.</P>
<P>We must be careful not to underestimate the difficulty in conducting trials in this area, and the problems with maintaining an intention-to-treat analysis, and full follow up in these rural communities. Since melioidosis remains an often fatal condition occurring in relatively isolated rural areas, further good quality research is needed to help identify best treatments.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-10 15:23:00 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>Intravenous therapy regimens should contain ceftazidime, imipenem, or the newer beta-lactam/beta-lactamase inhibitors. </P>
<P>Oral therapy: Regimens and length of treatment remain based on good clinical judgement, which is currently giving a combination of chloramphenicol, doxycycline, and trimethoprim-sulphamethoxazole treatment for about 20 weeks. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-10 15:23:00 +0000" MODIFIED_BY="[Empty name]">
<P>Further research on refining and improving treatment regimens are required, as well as testing new drugs. <LINK REF="REF-Vorachi-2000" TYPE="REFERENCE">Vorachi 2000</LINK> reports in vitro studies of a potentially promising new combination.</P>
<P>Better information on appropriate treatment of mild disease and for maintenance therapy is also required.</P>
<P>In designing trials, we suggest that:</P>
<P>1. concealment of allocation is conducted carefully and reported fully;</P>
<P>2. the studies use an intention-to-treat design and analysis (participants who die within 48 hours should be included in the primary analysis);</P>
<P>3. researchers should conduct trials that recruit participants during the acute stage of the illness and follow up these participants through the maintenance phase;</P>
<P>4. a classification of severity is established and standardized between trials - participants could be stratified by severity of their disease at the start of the trial.</P>
<P>Trials could be designed using a multicentred approach, or data combined between trials using an individual patient data analysis. In addition, better methods for prompt and rapid diagnosis may help clinicians to manage the patient successfully by initiating the therapy early, and this might also help in evaluating new treatments.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>David Machin (Singapore) for identifying the topic for review. Nick White (Thailand) for providing information about trials in progress. Paul Garner for helping with the analysis and drafting of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of this review (eg employment, consultancy, stock ownership, honoraria, expert testimony).<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Miny Samuel prepared the protocol, undertook searches, designed the data extraction form, extracted the data, conducted the analysis, contacted the trialists, and wrote the first draft of the review. Ti Teow Yee commented on the protocol and data extraction form, extracted data, and commented on the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-10 15:05:12 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chaowagul-1999" MODIFIED="2008-11-10 15:23:27 +0000" MODIFIED_BY="[Empty name]" NAME="Chaowagul 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-10 15:23:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaowagul W, Simpson A JH, Suputtamongkol Y, Smith MD, Angus BJ, and White NJ</AU>
<TI>A comparison of chloramphenicol, trimethoprim-sulphamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>375-80</PG>
<IDENTIFIERS MODIFIED="2008-11-10 15:23:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaowagul-2005" MODIFIED="2008-09-24 15:21:27 +0100" MODIFIED_BY="[Empty name]" NAME="Chaowagul 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-24 15:21:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, Maharjan B, Rajchanuwong A, Busarawong D, Limmathurotsakul D, Cheng AC, Wuthiekanun V, newton PN, White NJ, Day NPJ, Peacock SJ</AU>
<TI>Open-label randomized trial of oral trimethoprim-sulfamethoxazole. doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis</TI>
<SO>Antimicrobial agents and chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>10</NO>
<PG>4020-4025</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2007" MODIFIED="2008-09-24 15:53:17 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-09-24 15:53:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Withiekanun V, Stephens DP, Day NPJ, White NJ, Chaowagul W, Currie BJ, and Peacock SJ</AU>
<TI>A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>308-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chetchotisakd-2001a" NAME="Chetchotisakd 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B</AU>
<TI>Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimaxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chetchotisakd-2001b" NAME="Chetchotisakd 2001b" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B</AU>
<TI>Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>64</VL>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chierakul-2005" MODIFIED="2008-09-24 15:19:00 +0100" MODIFIED_BY="[Empty name]" NAME="Chierakul 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-24 15:19:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chierakul W, Anunnatsiri S, Short JM, Maharjan B, Mootsikapun P, Simpson AJH, Limmathurutsakul D, Cheng AC, Stepniewska, newton PN, Chaowagul W, White NJ, Peacock SJ, Day NP, Chetchotisakd P</AU>
<TI>Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>1105-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajchanuvong-1995" MODIFIED="2008-11-10 15:23:35 +0000" MODIFIED_BY="[Empty name]" NAME="Rajchanuvong 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-10 15:23:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rajchanuvong A., Chaowagul W., Suputtamongkol Y., Smith M. D., Dance D. A. B. and White N. J. (1995): A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline and co-trimoxazole for the oral maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 546-549.&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:23:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DAB, White NJ</AU>
<TI>A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline and co-trimoxazole for the oral maintenance treatment of melioidosis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>89</VL>
<PG>546-9</PG>
<IDENTIFIERS MODIFIED="2008-11-10 15:23:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1999" NAME="Simpson 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson AJH, Suputtamongkol Y, Smith MD, Angus BJ, Rajchanuvong A, Wuthiekanun et al</AU>
<TI>Comparison of imipenem and ceftazidime as therapy for severe melioidosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>381-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99404396"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sookpranee-1992" NAME="Sookpranee 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Sookpranee M., Boonma P., Susaengrat W., Bhuripanyo K., Punyagupta S. (1992): Multicentre prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrobial Agents And Chemotherapy, 36, 158-162.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S</AU>
<TI>Multicentre prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>158-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92272542"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suputtamongkol-1994a" MODIFIED="2008-11-10 15:23:39 +0000" MODIFIED_BY="[Empty name]" NAME="Suputtamongkol 1994a" YEAR="1994">
<REFERENCE MODIFIED="2008-11-10 15:23:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Suputtamongkol Y., Rajchanuvong A.,Chaowagul W., Dance D. A. B., Smith M. D., Wuthiekanun V., Walsch A. L., Pukrittayakamee S. and White N. J. (1994): Ceftazidime vs. Amoxycillin/Clavulanate in the treatment of severe melioidosis. Clinical Infectious Diseases, 19, 846-853.&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:23:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suputtamongkol Y, Rajchanuvong A, Chaowagul W, Dance DAB, Smith MD, Wuthiekanun V et al</AU>
<TI>Ceftazidime vs. amoxycillin/clavulanate in the treatment of severe melioidosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>5</NO>
<PG>846-53</PG>
<IDENTIFIERS MODIFIED="2008-11-10 15:23:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thamprajamchit-1998" MODIFIED="2008-11-10 15:23:43 +0000" MODIFIED_BY="[Empty name]" NAME="Thamprajamchit 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-10 15:23:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Thamprajamchit S., Chetchotisakd P. and Thinkhamrop, B. (1998): Cefoperazone/Sulbactam+Co-trimoxazole vs ceftazidime+co-trimoxazole in the treatment of severe melioidosis: A randomised, double-blind, controlled study. Journal of Medical association of Thailand, 81, 265-271&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:23:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thamprajamchit S, Chetchotisakd P, Thinkhamrop B</AU>
<TI>Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomised, double-blind, controlled study</TI>
<SO>Journal of Medical Association of Thailand</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>4</NO>
<PG>265-71</PG>
<IDENTIFIERS MODIFIED="2008-11-10 15:23:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1989" MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]" NAME="White 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;White N. J., Dance D. A. B., Chaowagul W., Wattanagoon Y., Wuthiekanun V., Pitakwatchara N. (1989) : Halving of mortality of severe melioidosis by ceftazidime. The Lancet , ii, 697-701.&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 15:23:49 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N</AU>
<TI>Halving of mortality of severe melioidosis by ceftazidime</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>8665</NO>
<PG>697-701</PG>
<IDENTIFIERS MODIFIED="2008-11-10 15:23:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-10 15:21:44 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Angus-2000" MODIFIED="2008-11-10 15:21:44 +0000" MODIFIED_BY="[Empty name]" NAME="Angus 2000" YEAR="">
<REFERENCE MODIFIED="2008-11-10 15:21:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V et al</AU>
<TI>Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis</TI>
<SO>British Journal of Pharmacology</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>5</NO>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Study-1" NAME="Study 1" YEAR="2000">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-10 15:22:29 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-10 15:22:29 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Brett-2000" NAME="Brett 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brett PJ, Woods DE</AU>
<TI>Pathogenesis of and immunity to melioidosis</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<PG>201-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaowagul-1989" MODIFIED="2008-08-19 16:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Chaowagul 1989" TYPE="JOURNAL_ARTICLE">
<AU>Chaowagul W, White NJ, Dance DAB, Wattangoon Y, Naigowit P, Davis TME et al</AU>
<TI>Melioidosis: a major cause of community -acquired septicemia in north eastern Thailand</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>159</VL>
<PG>890-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaowagul-1993" MODIFIED="2008-08-19 16:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Chaowagul 1993" TYPE="JOURNAL_ARTICLE">
<AU>Chaowagul W, Suputtamongkol Y, Dance DAB, Rajchanuvong A, Pattara-Arechachai J, White NJ</AU>
<TI>Relapse in melioidosis: incidence and risk factors</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>1181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2008-11-10 15:22:29 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Optimal search strategy. Cochrane Reviewers&#8217; Handbook 4.1 [updated June 2000]; Appendix 5c</TI>
<SO>In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 2002, issue 3</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Currie-2000" NAME="Currie 2000" TYPE="JOURNAL_ARTICLE">
<AU>Currie BJ, Fisher DA, Howard DM, Burrow JNC, Sevanayagam S, Snelling PL et al</AU>
<TI>The epidemiology of melioidosis in Australia and Papua New Guinea</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dance-1989" MODIFIED="2008-08-19 16:35:49 +0100" MODIFIED_BY="[Empty name]" NAME="Dance 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dance DAB, Davis TME, Wattanagoon Y, Chaowagul W, Saiphan P, Looareesuwan S et al</AU>
<TI>Acute suppurative parotitis caused by Pseudomonas pseudomallei in children</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>159</VL>
<PG>654-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dance-1991" MODIFIED="2008-08-19 16:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Dance 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dance DAB</AU>
<TI>Pseudomonas pseudomallei: danger in the paddy fields</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>85</VL>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dance-2000a" NAME="Dance 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Dance DAB</AU>
<TI>Melioidosis as an emerging global problem</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<NO>2-3</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dance-2000b" NAME="Dance 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Dance DAB</AU>
<TI>Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<PG>159-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howe-1971" NAME="Howe 1971" TYPE="JOURNAL_ARTICLE">
<AU>Howe C, Sampath A, Spotnitz M</AU>
<TI>The pseudimallei group: a review</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1971</YR>
<VL>124</VL>
<PG>598-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inglis-2001" NAME="Inglis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Inglis TJJ, Mee BJ, Chang BJ</AU>
<TI>The environmental microbiology of melioidosis</TI>
<SO>Reviews in Medical Microbiology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>1</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ip-1995" MODIFIED="2008-08-19 16:36:14 +0100" MODIFIED_BY="[Empty name]" NAME="Ip 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ip M, Osterberg LG, Chau PY, Raffin TA</AU>
<TI>Pulmonary melioidosis</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>1420-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenkins-1990" MODIFIED="2008-08-19 16:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Jenkins 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jenkins DR, Lewis AM, Strachan CJL</AU>
<TI>Imported melioidosis in a British native</TI>
<SO>Journal of Infection</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>221-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leelarasamee-1989" MODIFIED="2008-08-19 16:36:22 +0100" MODIFIED_BY="[Empty name]" NAME="Leelarasamee 1989" TYPE="JOURNAL_ARTICLE">
<AU>Leelarasamee A, Bovornkitti S</AU>
<TI>Melioidosis: review and update</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>413-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leelarasamee-1998" MODIFIED="2008-08-19 16:44:19 +0100" MODIFIED_BY="[Empty name]" NAME="Leelarasamee 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leelarasamee A</AU>
<TI>Burkhholderia pseudomallei: the unbeatable foe?</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>2</NO>
<PG>410-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leelarasamee-2000" NAME="Leelarasamee 2000" TYPE="JOURNAL_ARTICLE">
<AU>Leelarasamee A</AU>
<TI>Melioidosis in Southeast Asia</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mays-1975" MODIFIED="2008-08-19 16:41:55 +0100" MODIFIED_BY="[Empty name]" NAME="Mays 1975" TYPE="JOURNAL_ARTICLE">
<AU>Mays EE, Ricketts EA</AU>
<TI>Melioidosis: Recrudescence associated with bronchogenic carcinoma twenty six years following initial geographic exposure</TI>
<SO>Chest</SO>
<YR>1975</YR>
<VL>68</VL>
<PG>261-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minassian-1999" NAME="Minassian 1999" TYPE="JOURNAL_ARTICLE">
<AU>Minassian M A, Gage A, Price E, Sefton AM</AU>
<TI>Imipenem for the treatment of melioidosis</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>3</NO>
<PG>263-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perret-1998" NAME="Perret 1998" TYPE="JOURNAL_ARTICLE">
<AU>Perret JL, Vidal D, Thibault F</AU>
<TI>Pulmonary melioidosis</TI>
<SO>Revue de Pneumologie Clinique</SO>
<YR>1998</YR>
<VL>54</VL>
<NO>6</NO>
<PG>365-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suputtamongkol-1994b" MODIFIED="2008-08-19 16:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="Suputtamongkol 1994b" TYPE="JOURNAL_ARTICLE">
<AU>Suputtamongkol Y, Hall AJ, Dance DAB, Chaowagul W, Rajchanuvong A, Smith MD et al</AU>
<TI>The epidemiology of melioidosis in Ubon Ratchatani, Northeast Thailand</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1994</YR>
<VL>23</VL>
<PG>1082-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tiangpitayakorn-1997" NAME="Tiangpitayakorn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tiangpitayakorn C, Songsivilai S, Piyasangthong N, Dharakul T</AU>
<TI>Speed of detection of B. pseudomallei in blood cultures and its correlation with the clinical outcome</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>57</VL>
<PG>96-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vorachi-2000" NAME="Vorachi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vorachi M, Chongtrakool P, Arkomsean S, Boonsong S</AU>
<TI>Antimicrobial resistance in Burkholderia pseudomallei</TI>
<SO>Acta Tropica</SO>
<YR>2000</YR>
<VL>74</VL>
<NO>2-3</NO>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilks-1994" NAME="Wilks 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wilks D, Jacobsob SK, Lever AM, Farrington P</AU>
<TI>Fatal melioidosis in a tourist returning from Thailand</TI>
<SO>Journal of Infection</SO>
<YR>1994</YR>
<VL>29</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-10 15:21:07 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-10 15:21:07 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-10 15:20:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaowagul-1999">
<CHAR_METHODS>
<P>Allocation: Open label randomization.</P>
<P>Blinded: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Group 1: Survivors of severe melioidosis after parenteral treatment of ceftazidime (120 mg/kg dose), imipenum (50 mg/kg dose), or co-amoxiclav (160 mg/kg dose).</P>
<P>Group 2: People with mild localized disease who did not require intravenous treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 15:20:39 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Chloramphenicol (40 mg/kg dose) for the first 4 weeks only, doxycycline (4 mg/kg dose) and trimethoprim and sulpha-methoxazole (8 to 40 mg/kg dose).</P>
<P>Group 2: Doxycycline (4 mg/kg dose).</P>
<P>The treatment was for a minimum of 12 weeks and an average of 20 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-19 16:29:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Death.<BR/>2. Clinical failure (failure to improve during administration of therapy).<BR/>3. Culture confirmed relapses.<BR/>4. Adverse side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-24 15:48:09 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Sappasitprasong hospital, Ubon Ratchathani, Thailand.</P>
<P>Study period: October 1994 to August 1997.</P>
<P>Follow-up period: Up to September 1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:20:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaowagul-2005">
<CHAR_METHODS MODIFIED="2008-09-24 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: The study was an open-label randomisation. Rndomization was performed by a computer-generated sequence and was balanced after each block of 10 patients. Sealed envelopes were prepared by a member of the research unit who was not involved in enrollment.<BR/>Blinding: Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-24 15:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Patients who were 15 years or older and had either completed an intravenous course of appropriate antibiotics for culture confirmed severe melioidosis or patients with mild disease who did not require intravenous antibiotics.<BR/>
<BR/>Survivors of severe melioidosis after parenteral treatment of ceftazidime (120 mg/kg dose), imipenum (50 mg/kg dose) or co-amoxiclav (160 mg/kg dose).<BR/>2. Patients with mild localised disease who did not require intravenous treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 15:20:48 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Trimethoprim-sulfamethoxazole (TMP- SMX), doxycycline and chloramphenicol combination. Dose: 8 mg/kg TMP/daily up to a maximum dose of 160mg/kg twice daily, 40 mg/kg SMX daily up to a maximum dose of 800 mg/kg twice daily , doxycycline 4mg/kg daily up to a maximum dose of 100mg twice daily, and chloramphenicol 40mg/kg daily up to a maximum dose of 500 mg 4 times daily for first 4 weeks of therapy.<BR/>
<BR/>Group 2: Trimethoprim-sulfamethoxazole (TMP- SMX), doxycycline and chloramphenicol combination. Dose: 8 mg/kg TMP/daily up to a maximum dose of 160mg/kg twice daily, 40 mg/kg SMX daily up to a maximum dose of 800 mg/kg twice daily , doxycycline 4mg/kg daily up to a maximum dose of 100mg twice daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 15:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Culture confirmed clinical relapse or time to death attributable to melioidosis</P>
<P>Secondary outcomes: Adverse events (Nausea, Vomiting, Abdominal pain, rash or other allergic reaction, photosensitivity, anemia, angular stomatitis, anorexia, chest discomfort, dry mouth, seizure, azotemia, other complications).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-24 15:45:11 +0100" MODIFIED_BY="[Empty name]">
<P>Study was conducted in Sappasithiprasong Hospital, Ubon Ratchathani, NorthEast Thailand.<BR/>Study period: Between July 1998 to October 2002.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:12:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2007">
<CHAR_METHODS MODIFIED="2008-11-10 15:12:19 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:12:22 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 15:12:22 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 15:12:22 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-10 15:12:23 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:29:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chetchotisakd-2001a">
<CHAR_METHODS>
<P>Allocation: Restricted randomization in blocks of 4. </P>
<P>The hospital pharmacist provided the medication to participants after enrollment in the study. </P>
<P>Blinding: Double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>People clinically diagnosed with severe melioidosis from bacterial infection (Burkholderia pseudomallei).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-19 16:29:44 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1: Cefoperazone-Sulbactum (ratio 1:1; 25 mg/kg/day) usual 3 g/day in 3 divided doses plus cotrimoxazole (trimethoprim-sulfamethoxazole at a ratio of 80:400; trimethoprim, 8 mg/kg/day).</P>
<P>Group 2: Ceftazidime (100 mg/kg/day), 6 g per day in three divided doses and cotrimoxazole (8 mg/kg/day) 6 ampoules per day.</P>
<P>Vitamin K was given intravenously to both groups on days 1 and 7 to prevent bleeding from cefoperazone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-19 16:29:56 +0100" MODIFIED_BY="[Empty name]">
<P>Within 26 days:</P>
<P>1. Death.<BR/>2. Treatment failure.<BR/>3. Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Srinagarind Hospital, Thailand. </P>
<P>Study period: July 1995 to April 1999.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chetchotisakd-2001b">
<CHAR_METHODS>
<P>Allocation: Open label randomization.</P>
<P>Blinding: Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Participants had culture proven melioidosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Ciprofloxacin (Ciprobay: 20 mg/kg/day) 500 mg twice daily for 12 weeks and azithromycin (Zithromax: 500 mg daily) for 12 weeks.</P>
<P>Group 2: Cotrimoxazole (10 mg trimethoprim + 50 mg sulfamethoxazole/kg/day) usual dose 2 single tablets twice daily and doxycycline (Vibramycin, 4 mg/kg/day) usual dose 100 mg twice daily for 20 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Treatment failures: Fatal and clinical relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Sapprasitthiprasong Hospital and Srinagarind Hospital in Thailand. </P>
<P>Study period: August 1997 to July 1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-24 15:46:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chierakul-2005">
<CHAR_METHODS MODIFIED="2008-09-24 15:45:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: The study was randomised and double-blind. Rndomization was performed by a computer-generated sequence and was balanced after each block of 10 patients. Sealed envelopes were prepared by a member of the research unit who was not involved in enrollment.<BR/>Blinding: Blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-24 15:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>All adult patients (aged &gt;14 years with suspected severe melioidosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-24 15:46:00 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2008-09-24 15:46:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: In-hospital mortality rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-24 15:46:16 +0100" MODIFIED_BY="[Empty name]">
<P>One study was conducted in Sappasithiprasong Hospital, Ubon Ratchathani, NorthEast Thailand and the second study was conducted in Khon Kaen, Thailand.<BR/>Study period: Between 1999 to October 2003.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:31:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rajchanuvong-1995">
<CHAR_METHODS>
<P>Allocation: Open and randomized in pairs.</P>
<P>Blinding: Not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Group 1: Survivors of severe melioidosis after parenteral treatment.</P>
<P>Group 2: People with non-severe or localized culture proven melioidosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-19 16:31:34 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1:<BR/>Chloramphenicol (40 mg/kg/day) x 4 times per day for 8 to 20 weeks.<BR/>Doxycycline (4 mg/kg/day) x 2 times per day for 20 weeks.<BR/>Co-trimoxazole [trimethoprim 10 mg/kg per day and sulphamethoxazole 50 mg/kg/day] for 20 weeks.</P>
<P>Group 2:<BR/>Co-amoxiclav (250 mg amoxycillin and 125 mg clavulanic acid) daily for 20 weeks.<BR/>Amoxycillin (30 mg/kg/day) x 4 per day for 20 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-19 16:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Survived and cured.<BR/>2. Relapse: Culture proven, clinical, fatal.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: North East Thailand.</P>
<P>Study period: Participants seen between June 1989 and October 1992.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Simpson-1999">
<CHAR_METHODS>
<P>Allocation: Restricted randomization in blocks of 10.</P>
<P>Blinding: Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>People clinically diagnosed with severe melioidosis from bacterial infection (Burkholderia pseudomallei).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Imipenum/ cilastatin sodium at a dosage of 50 mg/kg dose (usual 1 g of imipenum 3 times daily by infusion).</P>
<P>Group 2: Ceftazidime at a dosage of 120 mg/kg dose (usual adult dose, 2 g three times daily by bolus injection).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death or treatment failure at 10 to 14 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Sappasitprasong hospital in Ubon Ratchathani, Thailand. </P>
<P>Study period: July 1994 to November 1997.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:21:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sookpranee-1992">
<CHAR_METHODS>
<P>Allocation: Randomized, predetermined random number.</P>
<P>Blinding: Not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Group 1: People clinically diagnosed with septicaemia from bacterial infection (Burkholderia pseudomallei).</P>
<P>Group 2: People with moderate to severe clinical sepsis that manifested by altering vital signs respiratory rate, impending shock, and evidence of dissemination of infection. 51 (84%) had underlying diseases (diabetes or renal failure).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 15:21:00 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Ceftazidime (100 mg/kg/day) with co-trimoxazole (trimethoprim [8 mg/kg/day] sulpha-methoxazole (40 mg/kg/day]) IV 8 hourly.</P>
<P>Group 2: Chloramphenicol (100 mg/kg/day) IV 6 hourly, doxycycline (4 mg/kg/day) IV I2 hourly, co-trimoxazole (trimethoprim [8 mg/kg/day] sulpha-methoxazole [40 mg/kg/day]) IV 8 hourly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival at 7 days.</P>
<P>Bacterial clearance on days 1, 3, and 7.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Srinagarind and Khon Kaen hospitals, Thailand.</P>
<P>Study period: September 1986 to January 1989.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Suputtamongkol-1994a">
<CHAR_METHODS>
<P>Allocation: Randomized in pairs.</P>
<P>Blinding: Not stated.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>People with culture-proven melioidosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Ceftazidime (120 mg/kg/day) IV 8 hourly.</P>
<P>Group 2: Amoxycillin (120 mg/kg/day) clavulanate (160 mg/kg/day) IV 4 hourly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death at 7 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Ubon Ratchatani, Northeastern Thailand.</P>
<P>Study period: January 1989 and October 1992.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-19 16:32:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thamprajamchit-1998">
<CHAR_METHODS>
<P>Allocation: Randomized (not described further).</P>
<P>Blinding: Double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>People with clinical sepsis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Cefoperazone- sulbactam (3 mg/kg/day); and co-trimoxazole (8 mg/kg/day) IV x 3 times a day.</P>
<P>Group 2: Ceftazidime (100 mg/kg/day) and co-trimoxazole (8 mg/kg/day) IV x 3 times a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-19 16:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Death.<BR/>2. Bacterial clearance at 24 and 48 hours; and at 2 and 6 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Srinagarind Hospital, Khon Kaen, Thailand </P>
<P>Study period: July 1995 to September 1996.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:21:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-1989">
<CHAR_METHODS>
<P>Allocation: Randomized in pairs.</P>
<P>Blinding: Not stated.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>People diagnosed with septicaemia (Burkholderia pseudomallei).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 15:21:07 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Ceftazidime (120 mg/kg/day) IV x 3 times daily.</P>
<P>Group 2 : Chloramphenicol succinate (100 mg/kg/day); doxycycline (4 mg/kg/day); trimethoprim (10 mg/kg/day); and sulpha-methoxazole (50 mg/kg/day) IV x 3 times daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The trial end point was survival at 14 days. Analysis of mortality in the two groups was on the basis of "intention to treat".</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: Ubon Ratchatani Hospital, Northeastern Thailand.</P>
<P>Study period: September 1986 to July 1988.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IV: intravenous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Angus-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although the study aimed to compare bacteriaemia clearance after infusion and bolus injections of ceftazidime, the high mortality precluded this and the authors were only able to report pharmacokinetics of ceftazidime in the disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-10 15:12:31 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-11-10 15:12:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Study-1">
<CHAR_STUDY_NAME>
<P>A oral maintenance therapy trial of doxycycline, trimethoprim and sulphamethoxazole versus the four-drug conventional regimen with or without chloramphenicol.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-10 15:12:29 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:12:29 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Doxycycline + trimethoprim + sulpha-methoxazole versus four-drug conventional regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 15:12:30 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-10 15:12:30 +0000" MODIFIED_BY="[Empty name]">
<P/>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-10 15:12:31 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>This study is in the early stages of enrolment.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-10 15:12:11 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-11-10 15:12:11 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-10 15:12:11 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-09-24 15:34:37 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-19 14:51:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Regimens with beta-lactam activity vs conventional regimens</NAME>
<DICH_OUTCOME CHI2="0.24601779268424423" CI_END="0.713305432306095" CI_START="0.2964310932635004" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45983247941972255" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.14672446851881277" LOG_CI_START="-0.528076244267183" LOG_EFFECT_SIZE="-0.3374003563929979" METHOD="MH" MODIFIED="2008-08-19 14:51:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6198931668705999" P_Q="0.0" P_Z="5.240550265328664E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="61" WEIGHT="100.0" Z="3.468149823629504">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours newer drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours older drugs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8146701289420264" CI_START="0.3086287361136206" DF="0.0" EFFECT_SIZE="0.5014285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.08901820743242522" LOG_CI_START="-0.5105636396644403" LOG_EFFECT_SIZE="-0.29979092354843273" NO="1" P_CHI2="1.0" P_Z="0.005307721516749722" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="27" WEIGHT="61.45299637326579" Z="2.787739437411483">
<NAME>Ceftazidime vs (chloramphenicol + doxycycline + trimethoprim + sulphamethoxazole)</NAME>
<DICH_DATA CI_END="0.8146701289420264" CI_START="0.3086287361136206" EFFECT_SIZE="0.5014285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.08901820743242522" LOG_CI_START="-0.5105636396644403" LOG_EFFECT_SIZE="-0.29979092354843273" ORDER="67" O_E="0.0" SE="0.2476178735766288" STUDY_ID="STD-White-1989" TOTAL_1="35" TOTAL_2="27" VAR="0.061314611314611314" WEIGHT="61.45299637326579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9372541614830681" CI_START="0.16522393901348092" DF="0.0" EFFECT_SIZE="0.39351851851851855" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.028142622600067946" LOG_CI_START="-0.7819270282732083" LOG_EFFECT_SIZE="-0.40503482543663816" MODIFIED="2008-08-19 14:51:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.035177006084081086" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="34" WEIGHT="38.54700362673421" Z="2.106314920726851">
<NAME>(Ceftazidime + co-trimoxazole) vs (chloramphenicol + doxycycline + co-trimoxazole)</NAME>
<DICH_DATA CI_END="0.9372541614830681" CI_START="0.16522393901348092" EFFECT_SIZE="0.39351851851851855" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.028142622600067946" LOG_CI_START="-0.7819270282732083" LOG_EFFECT_SIZE="-0.40503482543663816" ORDER="68" O_E="0.0" SE="0.4427766911853882" STUDY_ID="STD-Sookpranee-1992" TOTAL_1="27" TOTAL_2="34" VAR="0.19605119825708062" WEIGHT="38.54700362673421"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-09-24 15:11:20 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Ceftazidime regimens vs alternative beta-lactam/beta-lactamase inhibitors</NAME>
<DICH_OUTCOME CHI2="0.7150492055171287" CI_END="1.3895416332791852" CI_START="0.8056869326207954" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0580810631825885" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.14287156358733027" LOG_CI_START="-0.09383368009022368" LOG_EFFECT_SIZE="0.024518941748553316" METHOD="MH" MODIFIED="2008-09-24 15:11:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8696586683065148" P_Q="0.0" P_Z="0.6847110743998488" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="250" TOTAL_2="246" WEIGHT="100.0" Z="0.40604290821426425">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ceftazidime</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours others</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.983281620897408" CI_START="0.6967900320541596" DF="0.0" EFFECT_SIZE="1.1755555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.2973843872853452" LOG_CI_START="-0.1568980707656612" LOG_EFFECT_SIZE="0.07024315825984204" NO="1" P_CHI2="1.0" P_Z="0.5444373584932292" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="69" WEIGHT="27.022931609253458" Z="0.6061165599054662">
<NAME>Ceftazidime vs (amoxycillin + clavulanate)</NAME>
<DICH_DATA CI_END="1.983281620897408" CI_START="0.6967900320541596" EFFECT_SIZE="1.1755555555555555" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.2973843872853452" LOG_CI_START="-0.1568980707656612" LOG_EFFECT_SIZE="0.07024315825984204" ORDER="69" O_E="0.0" SE="0.26684776459359566" STUDY_ID="STD-Suputtamongkol-1994a" TOTAL_1="75" TOTAL_2="69" VAR="0.07120772946859903" WEIGHT="27.022931609253458"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.169895635269663" CI_START="0.343871115240617" DF="0.0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-09-24 15:11:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6773583828712484" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.323669057480553" Z="0.41607054642558644">
<NAME>(Ceftazidime + co-trimoxazole) vs (cefoperazone + sulbactam)</NAME>
<DICH_DATA CI_END="5.169895635269663" CI_START="0.343871115240617" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7134817760757654" LOG_CI_START="-0.46360430285916565" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="70" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Thamprajamchit-1998" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="4.323669057480553"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4833942848983124" CI_START="0.7361561550164375" DF="0.0" EFFECT_SIZE="1.0449927431059507" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.17125660146429675" LOG_CI_START="-0.13303005241701144" LOG_EFFECT_SIZE="0.019113274523642663" NO="3" P_CHI2="1.0" P_Z="0.8055088832358375" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="108" WEIGHT="55.68239216082432" Z="0.24622394189906838">
<NAME>Ceftazidime vs imipenum</NAME>
<DICH_DATA CI_END="1.4833942848983124" CI_START="0.7361561550164375" EFFECT_SIZE="1.0449927431059507" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" LOG_CI_END="0.17125660146429675" LOG_CI_START="-0.13303005241701144" LOG_EFFECT_SIZE="0.019113274523642663" ORDER="71" O_E="0.0" SE="0.17873948673310955" STUDY_ID="STD-Simpson-1999" TOTAL_1="106" TOTAL_2="108" VAR="0.03194780411761544" WEIGHT="55.68239216082432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9257206937088356" CI_START="0.3141360393442413" DF="0.0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.2845932973381821" LOG_CI_START="-0.5028822361883182" LOG_EFFECT_SIZE="-0.10914446942506803" NO="4" P_CHI2="1.0" P_Z="0.5869206432031179" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="12.97100717244166" Z="0.5433038109181271">
<NAME>(Ceftazidime + co-trimoxazole) vs (cefoperazone + sulbactam + co-trimoxazole)</NAME>
<DICH_DATA CI_END="1.9257206937088356" CI_START="0.3141360393442413" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2845932973381821" LOG_CI_START="-0.5028822361883182" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="72" O_E="0.0" SE="0.46256702646022446" STUDY_ID="STD-Chetchotisakd-2001a" TOTAL_1="50" TOTAL_2="50" VAR="0.21396825396825397" WEIGHT="12.97100717244166"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-09-24 15:34:37 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>New regimens vs conventional regimen for oral maintenance therapy</NAME>
<DICH_OUTCOME CHI2="0.5646976071640759" CI_END="4.231597215356346" CI_START="0.970769711669743" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.026797081272313" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.6265043226677031" LOG_CI_START="-0.01288378225759352" LOG_EFFECT_SIZE="0.3068102702050548" METHOD="MH" MODIFIED="2008-09-24 15:32:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7540106592301492" P_Q="0.0" P_Z="0.05997508168174394" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="129" WEIGHT="300.0" Z="1.8809767496665193">
<NAME>Death or fatal relapse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours doxy/co-amox</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.371712403385423" CI_START="0.5049158625041658" DF="0.0" EFFECT_SIZE="1.4857142857142858" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.6406515838057961" LOG_CI_START="-0.29678098523674906" LOG_EFFECT_SIZE="0.17193529928452353" NO="1" P_CHI2="1.0" P_Z="0.47216723498535473" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.0" Z="0.718957299751098">
<NAME>Amoxycillin + clavulanic acid vs chloramphenicol + doxycycline + co-trimoxazole</NAME>
<DICH_DATA CI_END="4.371712403385423" CI_START="0.5049158625041658" EFFECT_SIZE="1.4857142857142858" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6406515838057961" LOG_CI_START="-0.29678098523674906" LOG_EFFECT_SIZE="0.17193529928452353" ORDER="73" O_E="0.0" SE="0.5506525314216466" STUDY_ID="STD-Rajchanuvong-1995" TOTAL_1="49" TOTAL_2="52" VAR="0.3032182103610675" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.18821847969383" CI_START="0.13053629677999543" DF="0.0" EFFECT_SIZE="3.090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="1.8644411758526098" LOG_CI_START="-0.8842687120845498" LOG_EFFECT_SIZE="0.49008623188403005" NO="2" P_CHI2="1.0" P_Z="0.4846078505802991" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.6989106911770272">
<NAME>Ciprofloxacin + azithromycin vs co-trimoxazole + doxycycline</NAME>
<DICH_DATA CI_END="73.18821847969383" CI_START="0.13053629677999543" EFFECT_SIZE="3.090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8644411758526098" LOG_CI_START="-0.8842687120845498" LOG_EFFECT_SIZE="0.49008623188403005" ORDER="74" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Chetchotisakd-2001b" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.538022470140761" CI_START="0.8681425275471353" DF="0.0" EFFECT_SIZE="2.558139534883721" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.8772574277067933" LOG_CI_START="-0.061408968549516225" LOG_EFFECT_SIZE="0.40792422957863855" NO="3" P_CHI2="1.0" P_Z="0.08847147222716285" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="1.7035163964196423">
<NAME>Doxycycline vs chloramphenicol + trimethoprim + sulfamethoxazole + doxycycline</NAME>
<DICH_DATA CI_END="7.538022470140761" CI_START="0.8681425275471353" EFFECT_SIZE="2.558139534883721" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8772574277067933" LOG_CI_START="-0.061408968549516225" LOG_EFFECT_SIZE="0.40792422957863855" ORDER="75" O_E="0.0" SE="0.5513772876345551" STUDY_ID="STD-Chaowagul-1999" TOTAL_1="43" TOTAL_2="44" VAR="0.3040169133192389" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.763541678126738" CI_END="4.234019628440305" CI_START="1.3315268811997507" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3743864367022582" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.6267528670285877" LOG_CI_START="0.12434993850975197" LOG_EFFECT_SIZE="0.3755514027691698" METHOD="MH" MODIFIED="2008-09-24 15:33:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.41404908309417143" P_Q="0.0" P_Z="0.003387582552973784" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="129" WEIGHT="300.0" Z="2.930186836056521">
<NAME>Clinical relapse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours doxy/co-amox</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.667808611521396" CI_START="0.04967516967021868" DF="0.0" EFFECT_SIZE="0.5306122448979592" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.753415176726533" LOG_CI_START="-1.3038606408419244" LOG_EFFECT_SIZE="-0.2752227320576957" NO="1" P_CHI2="1.0" P_Z="0.5999943263792642" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.0" Z="0.5244086747661886">
<NAME>Amoxycillin + clavulanic acid vs chloramphenicol + doxycycline + co-trimoxazole</NAME>
<DICH_DATA CI_END="5.667808611521396" CI_START="0.04967516967021868" EFFECT_SIZE="0.5306122448979592" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.753415176726533" LOG_CI_START="-1.3038606408419244" LOG_EFFECT_SIZE="-0.2752227320576957" ORDER="76" O_E="0.0" SE="1.208453998919249" STUDY_ID="STD-Rajchanuvong-1995" TOTAL_1="49" TOTAL_2="52" VAR="1.4603610675039247" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1720970892813085" CI_START="1.265265861597435" DF="0.0" EFFECT_SIZE="2.558139534883721" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.7136666687496099" LOG_CI_START="0.1021817904076671" LOG_EFFECT_SIZE="0.40792422957863855" NO="2" P_CHI2="1.0" P_Z="0.008922718209242352" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="2.615001046512518">
<NAME>Doxycycline vs chloramphenicol + trimethoprim + sulphamethoxazole + doxycycline</NAME>
<DICH_DATA CI_END="5.1720970892813085" CI_START="1.265265861597435" EFFECT_SIZE="2.558139534883721" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.7136666687496099" LOG_CI_START="0.1021817904076671" LOG_EFFECT_SIZE="0.40792422957863855" ORDER="77" O_E="0.0" SE="0.3591892444370222" STUDY_ID="STD-Chaowagul-1999" TOTAL_1="43" TOTAL_2="44" VAR="0.1290169133192389" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.287670727401157E-31" CI_END="10.403838020757748" CI_START="0.9199767473698991" DF="0.0" EFFECT_SIZE="3.0937500000000004" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="100.00000000000001" ID="CMP-003.02.03" LOG_CI_END="1.0171935819668656" LOG_CI_START="-0.036223149411577706" LOG_EFFECT_SIZE="0.490485216277644" MODIFIED="2008-09-24 15:26:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.067975078408842" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="1.8251719955037609">
<NAME>Ciprofloxacin + azithromycin vs co-trimoxazole + doxycycline</NAME>
<DICH_DATA CI_END="10.403838020757748" CI_START="0.9199767473698989" EFFECT_SIZE="3.09375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0171935819668656" LOG_CI_START="-0.0362231494115778" LOG_EFFECT_SIZE="0.49048521627764397" ORDER="78" O_E="0.0" SE="0.6187822025086163" STUDY_ID="STD-Chetchotisakd-2001b" TOTAL_1="32" TOTAL_2="33" VAR="0.38289141414141414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.898895518138827" CI_END="1.487545871654279" CI_START="0.7620138122097616" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0646738939676177" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="51" I2="72.47427507670702" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.17247036700506468" LOG_CI_START="-0.11803715659725351" LOG_EFFECT_SIZE="0.027216605203905585" METHOD="MH" MODIFIED="2008-09-24 15:34:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.012285377365241268" P_Q="0.0" P_Z="0.7134370557023351" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="215" TOTAL_2="218" WEIGHT="400.0" Z="0.36724395512815344">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours doxy/co-amox</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0603999104802435" CI_START="0.1571079453127321" DF="0.0" EFFECT_SIZE="0.40816326530612246" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.025469682397591172" LOG_CI_START="-0.8038018511266561" LOG_EFFECT_SIZE="-0.3891660843645325" NO="1" P_CHI2="1.0" P_Z="0.06583139502922532" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.0" Z="1.8395699804560037">
<NAME>Amoxycillin + clavulanic acid vs chloramphenicol + doxycycline + co-trimoxazole</NAME>
<DICH_DATA CI_END="1.0603999104802437" CI_START="0.15710794531273206" EFFECT_SIZE="0.40816326530612246" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.025469682397591266" LOG_CI_START="-0.8038018511266563" LOG_EFFECT_SIZE="-0.3891660843645325" ORDER="79" O_E="0.0" SE="0.48711820375243786" STUDY_ID="STD-Rajchanuvong-1995" TOTAL_1="49" TOTAL_2="52" VAR="0.23728414442700158" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3572129952529588" CI_START="0.31882280618292713" DF="0.0" EFFECT_SIZE="0.6578073089700996" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.13264800934298246" LOG_CI_START="-0.49645062000760704" LOG_EFFECT_SIZE="-0.18190130533231227" NO="2" P_CHI2="1.0" P_Z="0.2570332368177267" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="1.1334312000017768">
<NAME>Doxycycline vs chloramphenicol + trimethoprim-sulphamethoxazole + doxycycline</NAME>
<DICH_DATA CI_END="1.3572129952529586" CI_START="0.31882280618292713" EFFECT_SIZE="0.6578073089700996" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.13264800934298238" LOG_CI_START="-0.49645062000760704" LOG_EFFECT_SIZE="-0.18190130533231227" ORDER="80" O_E="0.0" SE="0.36953564896897484" STUDY_ID="STD-Chaowagul-1999" TOTAL_1="43" TOTAL_2="44" VAR="0.1365565958589214" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.186289465186694" CI_START="0.18774363501565897" DF="0.0" EFFECT_SIZE="0.7734375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.5032852276555628" LOG_CI_START="-0.7264347777561998" LOG_EFFECT_SIZE="-0.11157477505031843" NO="3" P_CHI2="1.0" P_Z="0.7220934603276813" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.35566232917965446">
<NAME>Ciprofloxacin + azithromycin vs chloramphenicol + trimethoprim + sulphamethoxazole + doxycycline</NAME>
<DICH_DATA CI_END="3.186289465186694" CI_START="0.18774363501565897" EFFECT_SIZE="0.7734375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5032852276555628" LOG_CI_START="-0.7264347777561998" LOG_EFFECT_SIZE="-0.11157477505031843" ORDER="81" O_E="0.0" SE="0.7223436183910694" STUDY_ID="STD-Chetchotisakd-2001b" TOTAL_1="32" TOTAL_2="33" VAR="0.521780303030303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8627621216198493" CI_START="1.1435506977055125" DF="0.0" EFFECT_SIZE="1.8093406593406594" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="0.4567852622514501" LOG_CI_START="0.05825542320221589" LOG_EFFECT_SIZE="0.257520342726833" MODIFIED="2008-09-24 15:34:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.011310300621311775" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="89" WEIGHT="100.0" Z="2.532962642070321">
<NAME>Chloramphenicol+trimethoprim+sulfamethoxazole+doxycycline Vs trimethoprim+sulfamethoxazole+doxycycline</NAME>
<DICH_DATA CI_END="2.8627621216198493" CI_START="1.1435506977055128" EFFECT_SIZE="1.8093406593406594" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4567852622514501" LOG_CI_START="0.058255423202215974" LOG_EFFECT_SIZE="0.257520342726833" MODIFIED="2008-09-24 15:34:37 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.2340984002120396" STUDY_ID="STD-Chaowagul-2005" TOTAL_1="91" TOTAL_2="89" VAR="0.054802060981836265" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>